List of Excipients in Branded Drug TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION

« Back to Dashboard

Generic Drugs Containing TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION

Company	Ingredient	NDC	Excipient
Gland Pharma Limited	timolol maleate ophthalmic gel forming solution	68083-457	BENZODODECINIUM BROMIDE
Gland Pharma Limited	timolol maleate ophthalmic gel forming solution	68083-457	GELLAN GUM
Gland Pharma Limited	timolol maleate ophthalmic gel forming solution	68083-457	MANNITOL
Gland Pharma Limited	timolol maleate ophthalmic gel forming solution	68083-457	TROMETHAMINE

What are the Most Frequently-Used Excipients in TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION?

# Of NDCs	Excipient
3	BENZODODECINIUM BROMIDE
3	GELLAN GUM
3	MANNITOL
3	TROMETHAMINE

Timolol Maleate Ophthalmic Gel-Forming Solution: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 16, 2026

Timolol maleate ophthalmic gel-forming solution is a mature topical glaucoma product with limited active-ingredient differentiation and greater opportunity in delivery-system improvement. The commercial value is concentrated in once-daily dosing, reduced nasolacrimal drainage, preservative-free packaging, improved tolerability, and differentiated in situ gel technology. The reference product, TIMOPTIC-XE, uses a gellan-gum-based vehicle containing tromethamine, mannitol, polysorbate 80, benzododecinium bromide, and purified water. Its regulatory and commercial barriers are materially lower than those for a new chemical entity, but ophthalmic formulation equivalence remains technically demanding.

What is timolol maleate ophthalmic gel-forming solution?

Timolol maleate ophthalmic gel-forming solution is a topical beta-adrenergic blocker for reducing elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

The reference product, TIMOPTIC-XE, is supplied in 0.25% and 0.5% strengths. Timolol maleate is converted to timolol equivalent in the product label and acts primarily by reducing aqueous humor production. The gel-forming vehicle increases precorneal residence time and supports once-daily administration.[1]

Attribute	Reference product profile
Active ingredient	Timolol maleate
Dosage form	Ophthalmic gel-forming solution
Strengths	0.25% and 0.5%
Reference brand	TIMOPTIC-XE
Original sponsor	Merck
FDA application	NDA 020762
Indications	Ocular hypertension and open-angle glaucoma
Typical dosing	Once daily, depending on strength and clinical response
Primary gel former	Gellan gum
Preservative	Benzododecinium bromide
Administration route	Topical ophthalmic

Which excipients are used in timolol gel-forming solution?

The reference formulation uses a cation-activated polysaccharide system. Gellan gum remains fluid in the bottle but increases viscosity after contact with tear-fluid ions, particularly calcium and sodium. This creates an in situ gel on the ocular surface.

Excipient	Functional role	Commercial rationale
Gellan gum	Ion-activated gel former	Enables prolonged residence while maintaining bottle pourability
Tromethamine	Buffer and pH adjuster	Supports formulation stability and ocular tolerability
Mannitol	Tonicity and bulking agent	Helps match ocular tonicity and modulate vehicle properties
Polysorbate 80	Surfactant and wetting agent	Supports uniform dispersion and drop formation
Benzododecinium bromide	Preservative	Controls microbial growth in multidose packaging
Purified water	Vehicle	Continuous phase for the formulation

The excipient system has four design constraints: it must remain manufacturable as a low-viscosity liquid, gel rapidly after instillation, avoid excessive visual blurring, and deliver consistent dose volume over the product shelf life. Increasing polymer concentration can improve residence time but may also produce stringiness, poor drop formation, bottle residuals, and patient-reported blur.

What excipient strategies can improve the reference formulation?

Preservative-free multidose delivery

The clearest commercial opportunity is a preservative-free presentation. Chronic glaucoma therapy exposes patients to repeated administration over years. Benzalkonium chloride and other preservatives can aggravate ocular-surface disease, although the specific preservative in TIMOPTIC-XE is benzododecinium bromide.[1]

A preservative-free product could use:

• One-dose containers
• Multidose bottles with validated sterilizing valves
• Airless or metered-dose ophthalmic systems
• Blow-fill-seal packaging
• Antimicrobial container technologies compatible with ophthalmic use

The primary development risk is microbial control after repeated opening. A preservative-free multidose system requires container-closure validation, simulated-use testing, extractables and leachables assessment, and microbiological robustness under actual patient handling conditions.

Alternative gel-forming polymers

Potential substitutes or co-polymers include:

• Xanthan gum
• Carbomer
• Hydroxypropyl methylcellulose
• Sodium hyaluronate
• Poloxamer combinations
• Cellulose ether blends

Each alternative changes the product’s viscosity profile, ocular residence time, drop size, optical clarity, and regulatory comparability. Gellan gum has an important advantage because it produces ion-triggered gelation without requiring a highly viscous product in the bottle. Carbomer systems may provide strong mucoadhesion but can create greater blur or require tighter pH control.

Polymer-combination systems

A polymer combination could improve performance by separating functions:

• One polymer controls ion-triggered gelation.
• A second polymer improves mucoadhesion.
• A third component adjusts lubrication or surface hydration.

This approach can create formulation patent opportunities, particularly when the claim is tied to defined polymer ratios, viscosity ranges, gelation time, osmolality, and drug release. The risk is that a complex polymer system may move the product away from a conventional ANDA pathway.

Ocular-surface tolerability

Excipient selection should prioritize:

• Near-physiologic osmolality
• Moderate buffering capacity
• Low surfactant concentration
• Minimal preservative exposure
• Low irritation potential
• No visible particulate formation
• Stable pH during storage and use

Mannitol can support tonicity, but its concentration must be balanced against osmolality and comfort. Polysorbate 80 can improve wetting and dose uniformity but may introduce peroxide-related stability concerns. The formulation should control peroxide levels in excipients and packaging components because oxidative stress can affect drug stability and ocular tolerability.

What formulations are protected by timolol gel-forming solution patents?

Protection for this product category is more likely to arise from formulation and delivery claims than from the timolol molecule. Timolol maleate is an established active ingredient, so composition-of-matter protection is no longer commercially relevant.

Potential claim categories include:

1. An ophthalmic solution containing timolol maleate and gellan gum.
2. A gel-forming system activated by tear-fluid cations.
3. Defined polymer concentration ranges.
4. Specific pH and osmolality windows.
5. Once-daily treatment methods.
6. Preservative-free multidose packaging.
7. Container systems that maintain sterility during repeated use.
8. Manufacturing processes for dissolving, hydrating, filtering, and filling the polymer system.
9. Combination formulations containing timolol and another glaucoma active ingredient.

The strongest new patent position would combine formulation composition with measurable performance limitations, such as gelation time, viscosity at specified shear rates, drug release, drop volume, or ocular residence time. Broad claims covering “timolol and a gel-forming polymer” would face substantial prior-art pressure.

When does timolol maleate ophthalmic gel solution lose exclusivity?

The reference product is a mature small-molecule ophthalmic product. FDA regulatory exclusivity associated with the original approval has expired, and the principal commercial barriers are formulation development, bioequivalence, manufacturing validation, and market access rather than remaining new-drug exclusivity.[2]

The relevant exclusivity categories are:

Exclusivity type	Relevance
New chemical entity	Not available for timolol
Five-year NCE exclusivity	Not applicable
Three-year new clinical investigation exclusivity	No current commercial significance for the mature reference product
Orphan exclusivity	Not applicable
Pediatric exclusivity	Any historical period would have expired
Patent exclusivity	Depends on currently listed and enforceable formulation or method patents
Regulatory exclusivity for a new generic	Generally not available unless a first-filer qualifies under Paragraph IV rules

The Orange Book is the controlling FDA source for listed patents, approved strengths, therapeutic equivalence codes, and generic application status.[2] A current patent opinion should distinguish expired patents, unlisted patents, unenforceable claims, and method-of-use claims that may be carved out from an ANDA label.

What is the Orange Book status of TIMOPTIC-XE?

TIMOPTIC-XE is an FDA-approved reference product for timolol maleate ophthalmic gel-forming solution. Its commercial position differs from conventional timolol ophthalmic solution because the dosage form uses an in situ gel vehicle and a once-daily administration profile.

For generic applicants, the key Orange Book issues are:

• Whether the applicant can reference the gel-forming solution as the listed drug.
• Whether both 0.25% and 0.5% strengths are commercially and technically supportable.
• Whether any listed method-of-use patents require a label carve-out.
• Whether the proposed product meets the applicable ophthalmic bioequivalence framework.
• Whether the applicant can establish pharmaceutical equivalence for the excipient system.
• Whether the formulation’s physical properties remain within an acceptable range.

An ANDA applicant cannot assume that a conventional timolol solution is equivalent to a gel-forming solution. The dosage form, inactive ingredients, viscosity, drop size, drug release, and ocular exposure profile may materially affect the regulatory pathway.[3]

Which companies are challenging timolol gel-forming solution patents?

The product category is not associated with the type of active, high-value Paragraph IV litigation seen in major branded drugs. Generic competition is more likely to arise through abbreviated applications, product development by ophthalmic manufacturers, and formulation-specific filings than through large-scale patent litigation.

Relevant potential competitors include manufacturers with established ophthalmic capabilities, such as:

• Bausch + Lomb
• Akorn
• Sandoz
• Teva
• Viatris
• Apotex
• Amneal
• Lupin
• Dr. Reddy’s Laboratories

The commercial threat from these companies depends on whether they pursue an exact gel-forming equivalent, a different ophthalmic gel vehicle, or a conventional timolol solution positioned at a lower price.

What generic entry risks exist for timolol gel-forming solution?

Exact-equivalent generic launch

An exact-equivalent generic would compete directly on price while preserving once-daily dosing. The main development hurdles are:

• Reproducing the gelation profile
• Matching viscosity and drop volume
• Demonstrating equivalent drug availability
• Maintaining sterility and preservative effectiveness
• Controlling polymer variability
• Avoiding bottle clogging and dose inconsistency

Alternative formulation launch

A competitor may develop a different gel-forming system under an ANDA or a 505(b)(2) application. A 505(b)(2) route may be appropriate when the product differs in excipients, delivery system, dosing frequency, or performance characteristics from the reference product.[4]

A 505(b)(2) product can support differentiated claims, but it faces greater clinical, pharmacokinetic, or comparative-performance requirements than a conventional ANDA.

Conventional solution substitution

A lower-cost conventional timolol solution remains a commercial substitute. It may be dosed more frequently and may have a different preservative profile, but formularies can favor it because of price. The gel-forming product therefore needs to demonstrate value through adherence, comfort, reduced dosing frequency, or lower ocular-surface burden.

How strong is the patent estate for timolol gel-forming solution?

The legacy patent estate is likely weaker than the regulatory and manufacturing barriers surrounding the product. Timolol itself is off-patent, and broad gel-forming ophthalmic concepts have extensive prior art. The strongest defensible positions are narrower claims directed to:

• A defined gellan-gum concentration
• A specific buffering and tonicity system
• Preservative-free multidose packaging
• A polymer blend with demonstrated ocular performance
• A manufacturing process that produces a reproducible gelation profile
• A combination of timolol with another glaucoma therapy
• A specified viscosity or release profile tied to clinical performance

Patent strength should be assessed using claim breadth, prior-art density, written-description support, enablement, freedom-to-operate exposure, and the ability to detect infringement through routine product testing.

What licensing deals could support commercial entry?

The most practical licensing opportunities are likely to involve delivery platforms rather than timolol rights. Relevant assets include:

• Preservative-free multidose ophthalmic containers
• Ion-activated gel systems
• Thermosensitive ophthalmic polymers
• Sterile polymer hydration and filtration processes
• Ophthalmic combination-product platforms
• Low-volume metered-dose packaging

A license is most valuable when it reduces development time or resolves a manufacturing problem. A broad polymer patent with no validated ophthalmic product may have limited economic value because formulation and regulatory execution remain substantial.

How does timolol gel-forming solution compare with competing glaucoma products?

Product category	Dosing burden	Differentiation	Commercial pressure
Timolol conventional solution	Usually higher	Low price and familiarity	High
Timolol gel-forming solution	Once daily potential	Longer residence time	Moderate
Prostaglandin analogs	Usually once daily	Strong efficacy and established use	High
Fixed-combination glaucoma drops	One bottle for multiple actives	Convenience and adherence	Moderate to high
Preservative-free glaucoma products	Variable	Ocular-surface tolerability	Growing
Sustained-release implants or depot systems	Low administration frequency	Delivery innovation	Higher development cost

The gel-forming solution has its best commercial position in patients who need beta-blocker therapy but have adherence problems with multiple daily dosing or intolerance to conventional preserved drops.

What manufacturing and IP barriers affect commercial entry?

Manufacturing control is a central barrier. Gellan gum hydration, polymer lot variability, filtration behavior, mixing shear, and fill-finish conditions can change the finished product’s viscosity and gelation performance.

Critical process controls include:

• Polymer hydration time and temperature
• Mixing order
• Shear exposure
• pH adjustment sequence
• Sterile filtration feasibility
• Hold-time control
• Container compatibility
• Drop-size consistency
• Preservative distribution
• In-use stability

The most valuable manufacturing know-how may not be visible in published patent claims. Trade secrets covering polymer processing, sterile filtration, and filling can delay competitors even after formal patent expiry.

What is the revenue opportunity for a differentiated product?

Revenue potential is constrained by the maturity of timolol therapy and generic pricing. The strongest opportunities are niche or platform-based:

1. Preservative-free products for ocular-surface disease.
2. Multidose systems that reduce waste relative to single-dose packaging.
3. Fixed combinations with another glaucoma active.
4. Emerging-market products with stable room-temperature performance.
5. Contract development and manufacturing of gel-forming ophthalmic products.
6. Licensing of validated polymer and container technologies.
7. Reformulated products for adherence-sensitive patients.

A differentiated product should not rely solely on “once daily” labeling. It should quantify the commercial benefit through adherence data, tolerability outcomes, reduced rescue therapy, or improved persistence.

Key Takeaways

• Timolol maleate ophthalmic gel-forming solution is a mature small-molecule product with limited active-ingredient patent value.
• The reference formulation uses gellan gum, tromethamine, mannitol, polysorbate 80, benzododecinium bromide, and purified water.
• Preservative-free multidose delivery is the clearest commercial opportunity.
• Alternative polymers can create new formulation claims but may increase regulatory complexity.
• Exact generic substitution requires more than matching timolol strength; viscosity, gelation, drop size, sterility, and ocular performance are material.
• Biosimilar risk is not relevant because timolol is a chemically synthesized small molecule.
• A 505(b)(2) pathway may be useful for materially differentiated delivery systems.
• Manufacturing know-how may provide a stronger practical barrier than broad legacy formulation patents.
• The strongest new patent claims are likely to cover narrow polymer systems, container technologies, measurable performance parameters, and combination products.

FAQs

Is gellan gum safe for ophthalmic use?

Gellan gum is used as a pharmaceutical thickener and in situ gel-forming excipient. Its acceptability depends on concentration, purity, endotoxin control, ocular tolerability, and the complete formulation.

Can timolol maleate gel-forming solution be made preservative-free?

Yes. A preservative-free product requires either single-dose packaging or a validated multidose container-closure system that prevents microbial contamination during repeated use.

Is a timolol gel-forming solution automatically therapeutically equivalent to Timoptic-XE?

No. Therapeutic equivalence depends on the FDA-approved application, pharmaceutical equivalence, bioequivalence, labeling, and applicable product-specific requirements.

Can a new polymer create patent protection for a timolol ophthalmic product?

Yes, but protection is strongest when the polymer is claimed with defined composition ranges and demonstrated technical performance. Broad claims covering timolol with any ophthalmic gel former face significant prior-art risk.

What is the most attractive commercial improvement to TIMOPTIC-XE?

A preservative-free, once-daily, multidose gel-forming product with consistent drop size and low visual blur offers the clearest combination of patient value, formulation differentiation, and potential intellectual-property protection.

References

1. U.S. Food and Drug Administration. (n.d.). TIMOPTIC-XE (timolol maleate ophthalmic gel forming solution) prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Product-specific guidance for industry: Timolol maleate ophthalmic solution.
4. U.S. Food and Drug Administration. (2023). Applications covered by Section 505(b)(2).
5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.